Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening

Kanaoka, Shigeru; Yoshida, Kenichi; Miura, Naoyuki; Sugimura, Haruhiko; Kajimura, Masayoshi

doi:10.1053/j.gastro.2004.05.022

Cited by 64 publications

(74 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Human feces are a heterogeneous mixture of materials, including luxuriant populations of viable colonocytes (16,28). Because of the clinical availability of feces, we had previously optimized a method to extract fecal total RNA (17).…”

Section: Discussionmentioning

confidence: 99%

“…For the purpose of analyzing gene expression, fecal total RNA must first be purified from frozen feces (14). Upon examination, many genes were shown to change their expression in colorectal cancer patients (15,16). We previously established an organic solvent-free method of extracting fecal total RNA and revealed the aberrant presence of fecal CK19 to be a potential biomarker of colorectal cancer progression (17).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A homologue of the Drosophila headcase protein is a novel tumor marker for early-stage colorectal cancer

Chien

Chang²,

Yang

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

Abstract. The altered expression of certain genes is frequently detected as a hallmark of malignant tumors. These differentially expressed genes have the potential to become molecular markers. We purified the fecal mRNA from patients with colorectal cancer to identify novel candidates by using oligonucleotide microarray hybridization. We identified 21 upregulated and 22 downregulated candidates with significantly altered expression in patient fecal samples that have not been previously characterized. A gene encoding a homologue of the Drosophila headcase protein (HECA) was further examined due to its high ranking and possible importance in some human cancers. A tendency towards increased expression of HECA was dependent upon the clinicopathological stage. In this report, healthy individuals expressed less HECA, either in their blood samples or feces. Moreover, we detected upregulated HECA in blood and fecal samples of patients with colorectal cancer, and its expression level was shown to be significantly correlated with disease status. Our data show that HECA may be an early-stage classifier of colorectal cancer that can discriminate between late-and early-stage disease. In conclusion, this study is the first to analyze differentially expressed genes in the feces of colorectal cancer patients using oligonucleotide microarrays. The data suggest that HECA expression levels in feces may be an effective classifier for early-stage colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A homologue of the Drosophila headcase protein is a novel tumor marker for early-stage colorectal cancer

Chien

Chang²,

Yang

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…In these guidelines, the stool DNA test was recommended as a CRC screening method; however, the sensitivity and specificity of the stool DNA test was insufficient compared with fecal occult blood test (16). Several studies have reported an attempt to detect CRC by using reverse transcriptase-PCR in fecal samples (17)(18)(19). However, there is no evidence that the stool RNA test is useful for CRC screening.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening

Koga

Yasunaga

Takahashi

et al. 2010

Cancer Prevention Research

191

167

View full text Add to dashboard Cite

To reduce the colorectal cancer (CRC) mortality rate, we have reported several CRC screening methods using colonocytes isolated from feces. Expression analysis of oncogenic microRNA (miRNA) in peripheral blood was recently reported for CRC detection. In the present study, we conducted miRNA expression analysis of exfoliated colonocytes isolated from feces for CRC screening. Two hundred six CRC patients and 134 healthy volunteers were enrolled in the study. miRNA expression of the miR-17-92 cluster, miR-21, and miR-135 in colonocytes isolated from feces as well as frozen tissues was analyzed by quantitative realtime PCR. The expression of the miR-17-92 cluster, miR-21, and miR-135 was significantly higher in CRC tissues compared with normal tissues. The exfoliated colonocytes of 197 CRC patients and 119 healthy volunteers were analyzed because of the presence of sufficient miRNA concentration. miR-21 expression did not differ significantly between CRC patients and healthy volunteers (P = 0.6). The expression of miR-17-92 cluster and miR-135 was significantly higher in CRC patients than in healthy volunteers (P < 0.0001). The overall sensitivity and specificity by using miRNA expression was 74.1% (146/197; 95% confidence interval, 67.4-80.1) and 79.0% (94/119; 95% confidence interval, 70.6-85.9), respectively. Sensitivity was dependent only on tumor location (P = 0.0001). miRNA was relatively well conserved in exfoliated colonocytes from feces both of CRC patients and healthy volunteers. miRNA expression analysis of the isolated colonocytes may be a useful method for CRC screening. Furthermore, oncogenic miRNA highly expressed in CRC should be investigated for CRC screening tests in the future. Cancer Prev Res; 3(11); 1435-42. ©2010 AACR.

show abstract

“…Alexander and Raicht demonstrated the ability to extract RNA from stool and suggested its use as a method for the early detection of colon tumors (Alexander & Raicht, 1998). One such transcript with potentially diagnostic value is cyclooxygenase 2 (COX-2) which can separate colorectal cancer patients from healthy patients (Kanaoka et al, 2004). Still others are exploiting fecal RNA to better understand infant health (Chapkin et al, 2010;Davidson et al, 1995;Kaeffer et al, 2007).…”

Section: Fecesmentioning

confidence: 99%

Novel Tissue Types for the Development of Genomic Biomarkers

Sergueeva¹,

Collins²,

Dow³

et al. 2012

Biomarker

View full text Add to dashboard Cite

Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening

Cited by 64 publications

References 28 publications

A homologue of the Drosophila headcase protein is a novel tumor marker for early-stage colorectal cancer

A homologue of the Drosophila headcase protein is a novel tumor marker for early-stage colorectal cancer

MicroRNA Expression Profiling of Exfoliated Colonocytes Isolated from Feces for Colorectal Cancer Screening

Novel Tissue Types for the Development of Genomic Biomarkers

Contact Info

Product

Resources

About